|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | Examining patterns of traditional chinese medicine use in pediatric oncology: A systematic review, meta-analysis and data-mining study显示文摘Background Traditional Chinese medicine(TCM)is becoming a popular complementary approach in pediatric oncology.However,few or no meta-analyses have focused on clinical studies of the use of TCM in pediatric oncology.Objective We explored the patterns of TCM use and its efficacy in children with cancer,using a systematic review,meta-analysis and data mining study.Search strategy We conducted a search of five English(Allied and Complementary Medicine Database,Embase,PubMed,Cochrane Central Register of Controlled Trials,and ClinicalTrials.gov)and four Chinese databases(Wanfang Data,China National Knowledge Infrastructure,Chinese Biomedical Literature Database,and VIP Chinese Science and Technology Periodicals Database)for clinical studies published before October 2021,using keywords related to“pediatric,”“cancer,”and“TCM.”Inclusion criteria We included studies which were randomized controlled trials(RCTs)or observational clinical studies,focused on patients aged<19 years old who had been diagnosed with cancer,and included at least one group of subjects receiving TCM treatment.Data extraction and analysis The methodological quality of RCTs and observational studies was assessed using the six-item Jadad scale and the Effective Public Healthcare Panacea Project Quality Assessment Tool,respectively.Meta-analysis was used to evaluate the efficacy of combining TCM with chemotherapy.Study outcomes included the treatment response rate and occurrence of cancer-related symptoms.Association rule mining(ARM)was used to investigate the associations among medicinal herbs and patient symptoms.Results The fifty-four studies included in this analysis were comprised of RCTs(63.0%)and observational studies(37.0%).Most RCTs focused on hematological malignancies(41.2%).The study outcomes included chemotherapy-induced toxicities(76.5%),infection rate(35.3%),and response,survival or relapse rate(23.5%).The methodological quality of most of the RCTs(82.4%)and observational studies(80.0%)was rated as“moderate.”In studies of leukemia patients,adding TCM to conventional treatment significantly improved the clinical response rate(odds ratio[OR]=2.55;95%confidence interval[CI]=1.49-4.36),lowered infection rate(OR=0.23;95%CI=0.13-0.40),and reduced nausea and vomiting(OR=0.13;95%CI=0.08-0.23).ARM showed that Radix Astragali,the most commonly used medicinal herb(58.0%),was associated with treating myelosuppression,gastrointestinal complications,and infection.Conclusion There is growing evidence that TCM is an effective adjuvant therapy for children with cancer.We proposed a checklist to improve the quality of TCM trials in pediatric oncology.Future work will examine the use of ARM techniques on real-world data to evaluate the efficacy of medicinal herbs and drug-herb interactions in children receiving TCM as a part of integrated cancer therapy. | Chun Sing Lam Li Wen Peng Lok Sum Yang Ho Wing Janessa Chou Chi-Kong Li Zhong Zuo Ho-Kee Koon Yin Ting Cheung | 2022 | Journal of Integrative Medicine2022，20，5： | 2 |
| 3 | Loading and transport stress of juvenile matrinx? ( Brycon cephalus , Characidae) at various densities显示文摘 | Elisabeth Criscuolo Urbinati Janessa Sampaio de Abreu Ant?nio Cleber da Silva Camargo Miguel Angel Landinez Parra | 2004 | Aquaculture2004，，1： | 1 |
| 4 | Optimal Immunohistochemical Markers For Distinguishing Lung Adenocarcinomas From Squamous Cell Carcinomas in Small Tumor Samples显示文摘 | Jefferson Terry Samuel Leung Janessa Laskin | 2010 | Am J Surg Pathol2010，12，34： | 1 |
| 5 | Estimating Fluoride Exposure in Rural Communities: A Case Study in Western Wasbington显示文摘 | Janessa M William Daniell Frank James et a/ | 2009 | Wash State J Public Health Pract2009，2，2： | 1 |
| 6 | Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study显示文摘 | Lucio Crinò Eric Dansin Pilar Garrido Frank Griesinger Janessa Laskin Nick Pavlakis Daniel Stroiakovski Nick Thatcher Chun-Ming Tsai Yi-long Wu Caicun Zhou | 2010 | Lancet Oncology2010，，8： | 1 |
| 7 | DOCA and TGF-beta induce early growth response gene-I ( Egr-1 ) expression显示文摘 | Friedrich B Janessa A Artunc F et aI | 2008 | Cell Physiol Biochem2008，22，56： | 1 |
| 8 | Do exercise balls provide a training advantage for trunk extensor exercises? A biomechanical evaluation显示文摘 | Janessa D M D Steve L F Stephen H M B | 2006 | J Manipulative Physiol2006，29，5： | 1 |
| 9 | Acute effects of haemodialysis on pro-/anti apoptotic genes in peripheral blood leukoeytes 显示文摘 | Friedrich B Janessa A Schmieder R | 2008 | Cell Physiol Biochem2008，22，56： | 1 |
| 10 | DOCA and TGF-beta in- duce early growth response gene-1 ( Egr-1 ) expression 显示文摘 | Friedrich B Janessa A Artunc F | 2008 | Cell Physiol Biochem2008，22，56： | 1 |
| 11 | Elimination of electrocardiogram contamination from electromyogram signals: An evaluation of currently used removal techniques显示文摘 | Janessa D.M. Drake Jack P. Callaghan | 2005 | Journal of Electromyography and Kinesiology2005，，2： | 1 |
| 12 | Renal effects of the serine protease inhibitor aprotinin in healthy conscious mice显示文摘Treatment with aprotinin,a broad-spectrum serine protease inhibitor with a molecular weight of 6512 Da,was associated with acute kidney injury,which was one of the reasons for withdrawal from the market in 2007.Inhibition of renal serine proteases regulating the epithelial sodium channel ENaC could be a possible mechanism.Herein,we studied the effect of aprotinin in wild-type 129S1/SvImJ mice on sodium handling,tubular function,and integrity under a control and low-salt diet.Mice were studied in metabolic cages,and aprotinin was delivered by subcutaneously implanted sustained release pellets(2 mg/day over 10 days).Mean urinary aprotinin concentration ranged between 642±135(day 2)and 127±16(day 8)µg/mL.Aprotinin caused impaired sodium preservation under a low-salt diet while stimulating excessive hyperaldosteronism and unexpectedly,proteolytic activation of ENaC.Aprotinin inhibited proximal tubular function leading to glucosuria and proteinuria.Plasma urea and cystatin C concentration increased significantly under aprotinin treatment.Kidney tissues from aprotinin-treated mice showed accumulation of intracellular aprotinin and expression of the kidney injury molecule 1(KIM-1).In electron microscopy,electron-dense deposits were observed.There was no evidence for kidney injury in mice treated with a lower aprotinin dose(0.5 mg/day).In conclusion,high doses of aprotinin exert nephrotoxic effects by accumulation in the tubular system of healthy mice,leading to inhibition of proximal tubular function and counterregulatory stimulation of ENaC-mediated sodium transport. | Stefan Wörner Bernhard N.Bohnert Matthias Wörn Mengyun Xiao Andrea Janessa Andreas L.Birkenfeld Kerstin Amann Christoph Daniel Ferruh Artunc | 2022 | Acta Pharmacologica Sinica2022，43，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员